TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

What are the new therapeutic strategies in MCL?

Featured:

Julie VoseJulie Vose

Oct 26, 2023

Learning objective: After reading this article, learners will be able to cite a new clinical development in MCL.


During the Society of Hematologic Oncology (SOHO) 2023 Congress, the Lymphoma Hub spoke to Julie Vose, University of Nebraska Medical Center, Omaha, US. We asked, What are the new therapeutic strategies in Mantle cell lymphoma (MCL)?

What are the new therapeutic strategies in MCL?

Firstly, Vose discusses the efficacy and safety of novel treatment approaches, such CAR T-cell therapy, BTKis, and bispecific antibodies in MCL; brexucabtagene autoleucel, pirtobrutinib, and bispecific antibodies (specifically epcoritamab and glofitamab) for patients with R/R MCL were then discussed. With bispecific antibodies yet to be approved for R/R MCL, there remains an unmet need for treatment options in this patient group, who may require multiple treatments throughout their lifetime.